Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 30, 2026 | $1.21 | — | $1.29B | +66.9% | $1.63 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | $1.51 | — | $1.17B | +96.4% | $1.50 |
| Q4 FY25ended Dec 31, 2025 | — | $1.32 | — | $1.10B | +84.9% | — |
| Q3 FY25ended Sep 30, 2025 | — | $1.84 | — | $1.25B | +149.3% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$0.55 | — | $773.69M | +17.3% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$0.14 | — | $594.19M | +20.2% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$0.65 | — | $593.17M | +34.9% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$0.87 | −175.7% | $500.92M | −33.3% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Alnylam Pharmaceuticals shares, not any token. As of Jul 30, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 |
| — |
| −$0.13 |
| — |
| $659.83M |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.52 | — | $494.33M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$1.15 | — | $439.72M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $1.15 | — | $750.53M | — | — |